Aeva Technologies Inc
For the period ended Mar 31, 2024. Filed May 9, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2024 · Filed May 9, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Notes to the Condensed Financial Statements (Unaudited)
NOTES TO CONDENSED CONSOLIDATED FINAN CIAL STATEMENTS
Note 1. Description of Business and Summary of Significant Accounting Policies
Description of Business
Aeva Technologies, Inc. (the “Company”), through its Frequency Modulated Continuous Wave (“FMCW”) sensing technology, designs a 4D LiDAR-on-chip that, along with its proprietary software applications, has the potential to enable the adoption of LiDAR across broad applications from automated driving to consumer electronics, consumer health, industrial automation and security application.
The Company’s common stock and warrants are listed on the New York Stock Exchange stock market under the symbols “AEVA” and "AEVA.WS".
Basis of Presentation and Unaudited Interim Financial Statements
The condensed consolidated financial statements are prepared in accordance with accounting principles generally accepted in the United States of America ("U.S. GAAP"). The condensed consolidated financial statements include the accounts of the Company’s wholly-owned subsidiaries. All intercompany transactions and balances have been eliminated upon consolidation.
The accompanying condensed consolidated financial statements are unaudited and have been prepared on the same basis as the annual consolidated financial statements and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary to present fairly the Company’s financial position, results of operations, comprehensive loss and cash flows for the periods presented, but are not necessarily indicative of the results of operations to be anticipated for any future annual or interim period.
These condensed consolidated financial statements and other information presented in this Form 10-Q should be read in conjunction with the consolidated financial statements and the related notes included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2023 filed with the SEC.
On March 18, 2024, the Company filed a Certificate of Amendment to its Amended and Restated Certificate of Incorporation (the “Amendment”) with the Secretary of State of the State of Delaware to effect a 1-for-5 reverse stock split (the “Reverse Stock Split”) of the Company’s shares of common stock, $0.0001 par value (the “Common Stock”). Pursuant to the Reverse Stock Split, every five (5) shares of issued and outstanding shares of common stock were combined into one (1) share of common stock. Accordingly, unless we indicate otherwise, all the current period and historical per share data, number of shares issued and outstanding, stock awards, and other common stock equivalents for the periods presented in this Interim Report on Form 10-Q have been adjusted retroactively, where applicable, to reflect the Reverse Stock Split. There wasno change to the shares authorized or in the par value per share of common stock of $0.0001.
The Reverse Stock Split affected all stockholders uniformly and did not alter any stockholder’s percentage interest in the Company’s equity. The Company did not issue fractional shares in connection with the Reverse Stock Split. Stockholders who were otherwise entitled to fractional shares of common stock were instead entitled to receive a proportional cash payment. The number of shares of common stock issuable under our equity incentive plans and exercisable under the outstanding warrants were also proportionately adjusted.
Principles of Consolidation and Liquidity
The condensed consolidated financial statements are prepared in accordance with U.S. GAAP. The condensed consolidated financial statements include the accounts of the Company’s wholly-owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation.
The Company has funded its operations primarily through the Business Combination (the “Business Combination”) with InterPrivate Acquisition Corp. (the Company’s predecessor, which was originally incorporated in Delaware as a special purpose acquisition company (“IPV”)) on March 12, 2021, and issuances of stock. As of March 31, 2024, the Company’s existing sources of liquidity included cash and cash equivalents and marketable securities of $189.3 million. The Company has a limited history of operations and has incurred negative cash flows from operating activities and losses from operations in the past as reflected in the accumulated deficit of $494.9 million as of March 31, 2024. The Company expects to continue to incur operating losses due to the investments it intends to make in its business, including product development. Management believes that existing cash and cash equivalents and marketable securities will be sufficient to fund operating and capital expenditure requirements through at least 12 months from the date of issuance of these financial statements.
Significant Risks and Uncertainties
The Company is subject to those risks common in the technology industry and also those risks common to early stage companies including, but not limited to, the possibility of not being able to successfully develop or market its products, technological obsolescence, competition, dependence on key personnel and key external alliances, the successful protection of its proprietary technologies, compliance with government regulations, and the possibility of not being able to obtain additional financing when needed.
Concentration of Credit Risk
Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash, cash equivalents, marketable securities, and trade receivables. The Company maintains the majority of its cash and cash equivalents in accounts with large financial institutions. At times, balances in these accounts may exceed federally insured limits; however, to date, the Company has not incurred any losses on its deposits of cash and cash equivalents and believes the exposure to risk of loss is not material. Risks associated with the Company’s marketable securities is mitigated by investing in investment-grade rated securities when purchased.
The Company’s accounts receivable are derived from customers located in the United States, APAC, and Europe. The Company mitigates its credit risks by performing ongoing credit evaluations of its customers’ financial conditions and requires customer advance payments in certain circumstances.
As of March 31, 2024, three customers accounted for 44%,15% and 12% of the accounts receivable, respectively. As of December 31, 2023, one customer accounted for 42% of accounts receivable. As of March 31, 2024, one vendor accounted for 10% of the accounts payable. As of December 31, 2023, three vendors accounted for 12%,11% and 11% each of the accounts payable, respectively.
Recent Accounting Pronouncements
In November 2023, the Financial Standards Accounting Board (FASB) issued Accounting Standards Update (ASU) 2023-07 "Segment Reporting (Topic 280):Improvements to Reportable Segment Disclosures" which expands annual and interim disclosure requirements for reportable segments, primarily through enhanced disclosures about significant segment expenses. ASU 2023-07 is effective for our annual periods beginning January 1, 2024, and for interim periods beginning January 1, 2025, with early adoption permitted. The Company does not expect ASU 2023-07 to have a material impact on the Company's financial statements and related disclosures.
In December 2023, the FASB issued ASU 2023-09 "Income Taxes (Topics 740): Improvements to Income Tax Disclosures" to expand the disclosure requirements for income taxes, specifically related to the rate reconciliation and income taxes paid. ASU 2023-09 is effective for our annual periods beginning January 1, 2025, with early adoption permitted. We are currently evaluating the potential effect that the updated standard will have on our consolidated financial statements and related disclosures.
Note 2. Revenue
Disaggregation of Revenues
The Company disaggregates its revenue from contracts with customers by geographic region based on the primary billing address of the customer and timing of transfer of goods or services to customers (point-in-time or over time), as it believes it best depicts how the nature, amount, timing and uncertainty of its revenue and cash flows are affected by economic factors. Total revenue for the three months ended March 31, 2024 and 2023, based on the disaggregation criteria described above were as follows (in thousands):
| Three Months Ended March 31, | ||||
|---|---|---|---|---|
| 2024 | 2023 | |||
| Revenue | % of Revenue | Revenue | % of Revenue | |
| Revenue by primary geographical market: | ||||
| North America | $1,674 | 79% | $730 | 64% |
| EMEA | 229 | 11% | 244 | 21% |
| Asia | 204 | 10% | 174 | 15% |
| Total | $2,107 | 100% | $1,148 | 100% |
| Revenue by timing of recognition: | ||||
| Recognized at a point in time | $1,714 | 81% | $947 | 82% |
| Recognized over time | 393 | 19% | 201 | 18% |
| Total | $2,107 | 100% | $1,148 | 100% |
For the three months ended March 31, 2024, two customers accounted for 39% and 36% of the Company’s revenue, respectively. For the three months ended March 31, 2023, three customers accounted for 20%,19% and 17% of the Company’s revenue, respectively.
Contract Assets and Contract Liabilities
As of March 31, 2024, and December 31, 2023, the Company had contract assets of $0.1 million and $0.1 million, respectively, recognized in other current assets. As of March 31, 2024, and December 31, 2023, the Company had contract liabilities of $3.6 millionand $2.1 million, respectively, recognized in other current liabilities.
Note 3. Financial Instruments
The following tables summarize the Company’s financial assets and liabilities measured at fair value by level within the fair value hierarchy:
| Adjusted Cost | Unrealized Gains | Unrealized Losses | Fair Value | Cash and Cash Equivalent | Marketable Securities | |
|---|---|---|---|---|---|---|
| (in thousands) | ||||||
| Assets | ||||||
| Cash | $17,668 | $— | $— | $17,668 | $17,668 | $— |
| Money market funds | 264 | — | — | 264 | 264 | — |
| U.S. agency securities | 27,635 | 2 | (76) | 27,561 | — | 27,561 |
| U.S. Treasury securities | 30,255 | — | (41) | 30,214 | 11,673 | 18,541 |
| Commercial paper | 42,591 | 6 | (45) | 42,552 | — | 42,552 |
| Corporate bonds | 71,163 | 20 | (114) | 71,069 | — | 71,069 |
| Subtotal | 171,644 | 28 | (276) | 171,396 | 11,673 | 159,723 |
| Total assets | $189,576 | $28 | $(276) | $189,328 | $29,605 | $159,723 |
| Liabilities | ||||||
| Warrant liabilities | 7,209 | — | — | 7,209 | — | — |
| Total liabilities | $7,209 | $— | $— | $7,209 | $— | $— |
| Adjusted Cost | Unrealized Gain | Unrealized Losses | Fair Value | Cash and Cash Equivalent | Marketable Securities | |
|---|---|---|---|---|---|---|
| (in thousands) | ||||||
| Assets | ||||||
| Cash | $21,799 | $— | $— | $21,799 | $21,799 | $— |
| Money market funds | 6,266 | — | — | 6,266 | 6,266 | — |
| U.S. Government securities | 35,962 | 8 | (97) | 35,873 | — | 35,873 |
| U.S. Treasury securities | 18,323 | 1 | (14) | 18,310 | 10,482 | 7,828 |
| Commercial paper | 38,491 | 25 | (16) | 38,500 | — | 38,500 |
| Corporate bonds | 100,274 | 136 | (130) | 100,280 | — | 100,280 |
| Subtotal | 193,050 | 170 | (257) | 192,963 | 10,482 | 182,481 |
| Total assets | $221,115 | $170 | $(257) | $221,028 | $38,547 | $182,481 |
| Liabilities | ||||||
| Warrant liabilities | 6,772 | — | — | 6,772 | — | — |
| Total liabilities | $6,772 | $— | $— | $6,772 | $— | $— |
The fair value of the private placement and Series A warrant liabilities is based on significant unobservable inputs, which represent Level 3 measurements within the fair value hierarchy. In determining the fair value of the warrant liabilities, the Company used the Black-Scholes option-pricing model to estimate the fair value using unobservable inputs including the expected term, expected volatility, risk-free interest rate, and dividend yield.
The following table presents a summary of the changes in the fair valueof the Company’s Level 3 financial instruments (in thousand):
| March 31, 2024 | December 31, 2023 | |
|---|---|---|
| Fair value, beginning balance | $6,772 | $90 |
| Fair value at issuance of Series A warrants | — | $6,450 |
| Change in the fair value of Series A warrants included in other income (expense), net | 450 | $300 |
| Change in the fair value of private placement warrants included in other income (expense), net | (13) | (68) |
| Fair value, closing balance | $7,209 | $6,772 |
The key inputs into the Black-Scholes option pricing model for the private warrants were as follows for the relevant periods:
| March 31, 2024 | December 31, 2023 | |
|---|---|---|
| Expected term (years) | 2.0 | 2.2 |
| Expected volatility | 90.3% | 94.1% |
| Risk-free interest rate | 5.03% | 4.23% |
| Dividend yield | 0% | 0% |
| Exercise Price | $57.50 | $57.50 |
The key inputs into the Black-Scholes option pricing model for the Series A warrants were as follows for the relevant periods:
| March 31, 2024 | December 31, 2023 | |
|---|---|---|
| Expected term (years) | 3.7 | 4.0 |
| Expected volatility | 92.1% | 87.2% |
| Risk-free interest rate | 4.29% | 3.89% |
| Dividend yield | 0% | 0% |
| Exercise Price | $5.00 | $5.00 |
Note 4. Acquisition of Intangible Assets
As of March 31, 2024, expected amortization expense relating to purchased intangible assets was as follows (in thousands):
| Remainder of 2024 | $675 |
| 2025 | 900 |
| 2026 | 825 |
| Total future amortization | $2,400 |
The Company recorded amortization expense related to the acquired intangible assets of $0.2 million each for the three months ended March 31, 2024 and March 31, 2023, respectively.
Note 5. Inventories
Inventories consisted of the following (in thousands):
| March 31, | December 31, | |
|---|---|---|
| 2024 | 2023 | |
| Raw materials | $1,583 | $2,178 |
| Work-in-progress | 60 | 136 |
| Finished goods | 520 | 60 |
| Total inventories | $2,163 | $2,374 |
Note 6. Property, Plant and Equipment
Property, plant and equipment consisted of the following (in thousands):
| March 31, | December 31, | |
|---|---|---|
| 2024 | 2023 | |
| Computer equipment | $2,944 | $2,795 |
| Lab equipment | 7,255 | 7,151 |
| Leasehold improvements | 3,312 | 3,148 |
| Construction in progress | 700 | 1,434 |
| Testing equipment | 1,752 | 1,455 |
| Manufacturing equipment | 5,743 | 4,269 |
| Furniture, fixtures and other equipment | 561 | 458 |
| Total property, plant and equipment | $22,268 | $20,710 |
| Less: accumulated depreciation | (9,716) | (8,596) |
| Total property, plant and equipment, net | $12,552 | $12,114 |
Depreciation related to property, plant, and equipment was$1.1 million and $0.7 million for the three months ended March 31, 2024 and March 31, 2023, respectively.
Note 7. Other current assets
Other current assets consisted of the following (in thousands):
| March 31, | December 31, | |
|---|---|---|
| 2024 | 2023 | |
| Prepaid expenses | $2,222 | $2,228 |
| Contract assets | 111 | 140 |
| Vendor deposits | 975 | 1,104 |
| Other current assets | 1,574 | 1,723 |
| Total other current assets | $4,882 | $5,195 |
Note 8. Other non-current assets
Other non-current assets consist of the following (in thousands):
| March 31, | December 31, | |
|---|---|---|
| 2024 | 2023 | |
| Non marketable equity investments | $5,000 | $5,000 |
| Security deposit | 1,062 | $1,116 |
| Other non-current assets | — | 16 |
| Total other non-current assets | $6,062 | $6,132 |
In November 2023, the Company made an investment in 700,440 Preferred Stock of a private company for a cash consideration of $5.0 million, which is classified as non-marketable equity investment. The Company’s investment in the private company represents less than 1% of total capitalization. The Company neither has significant influence over the private company nor does the investment amount to a controlling financial interest in the private company. The Company elected to apply the meas urement alternative, and as such, records the investment at cost minus impairment, if any, plus or minus changes resulting from qualifying observable price changes in orderly transactions. During the period ended March 31, 2024, the Company did not identify any impairment or observable price changes for this non-marketable equity investment.
Note 9. Financing transaction
Private Investment
On November 8, 2023, the Company entered into Subscription Agreements (the “Subscription Agreements”) with entities affiliated with Sylebra Capital Limited (“Sylebra”) and Adage Capital Management, providing for the purchase of an aggregate of 7,360,460 shares of the Company’s common stock, $0.0001 par value per share (the “PIPE Shares”), at a price of $2.90 per PIPE Share for an aggregate purchase price of approximately $21.4 million (the “Private Placement”). The PIPE Shares are recorded as outstanding common stock.
Standby Equity Purchase Agreement
On November 8, 2023, the Company also entered into a Standby Equity Purchase Agreement (the “Facility Agreement”) with entities affiliated with Sylebra, pursuant to which the Company will have the right, but not the obligation to sell to Sylebra up to $125 million of its shares of Preferred Stock, subject to satisfaction of certain conditions, by November 8, 2026. Each sale the Company requests under the Facility Agreement (each, an “Advance” and collectively, the “Advances”) may be for a number of shares of preferred stock with an aggregate value of at least $25.0 million but not more than $50.0 million (except with Sylebra’s consent).
When and if issued, the preferred stock will be issued at a price per share of $10,000. Holders of the preferred stock will be entitled to a quarterly dividend at the rate of 7.0% per annum payable in cash or in kind at the option of the Company. The preferred stock will have an initial liquidation preference of $12,000 per share, plus accrued dividends. The preferred stock will have no voting rights as a class or series except in such instances as required by Delaware law or certain matters enumerated in the facility agreement related to the protection of the preferred stock.
The preferred stock will be convertible at the option of the holders into the number of shares of Common Stock equal to $10,000 divided by the then-applicable conversion price. At any time after the two year anniversary of any issuance of any series of preferred stock, the Company will have the option to convert all (but not less than all) of any series of then-outstanding preferred stock by paying a make-whole payment, in either stock or cash, equal to three years of dividends, provided that the closing price of the Common Stock exceeds 250% of the then-applicable conversion price for at least 20 out of 30 consecutive trading days prior to the date of conversion. To the extent, if any, a conversion would result in the holder thereof becoming the beneficial owner of more than 19.9% of the Company’s outstanding Common Stock, the Company will issue the Investor Pre-Funded Warrant in the form attached to the Facility Agreement. The preferred stock will be subject to customary pre-emptive rights.
The Company’s right to request Advances is conditioned upon the Company achieving a minimum of one new passenger auto-original equipment manufacturer (“OEM”) or commercial OEM program award with at least a 50,000 unit volume, the trading price of the Common Stock being below $15 at the time of the Advance request and other customary conditions. Prior to any Advance, the Company will assess its capital needs and other factors, including the impact of an Advance on the Company’s outstanding executive pledge arrangements.
The Preferred Stock issued in connection with the facility agreement ranks senior to common stock upon the Company’s liquidation, dissolution or winding up. The Preferred Stock is entitled to priority cumulative dividends which shall accrue daily from and after the original issue date of such share and shall compound on a quarterly basis on each dividend payment date. The accrued dividends shall in all cases be payable upon liquidation.
The Company shall pay dividends on each share of Preferred Stock in cash or in kind through issuance of shares of common stock with an aggregate value equal to the amount of the dividend to have been paid divided by the dividend conversion price. The board of directors of the Company may at its sole discretion elect to pay the dividends in cash in lieu of shares of common stock. The Convertible Redeemable Preferred Stock have no voting rights unless they are converted into shares of common stock.
Holders may, at their option, elect to convert some or all Preferred Stock held by such holder, at any time and from time to time prior to a change of control, into a number of shares of common stock per share of the Preferred Stock equal to (x) the quotient of the issuance price divided by the conversion price in effect at the time of conversion. At any time on or after the two-year anniversary of the issuance date, the Company shall have the right to redeem the Preferred Stock of any holder outstanding at such time at the issuance price plus three (3) years of dividend payment (“Redemption price”); provided, that (a) the closing price of a share of common stock exceeds 250% of the then-applicable conversion price per share for at least 20 out of 30 consecutive trading days prior to the redemption date and (b) a shelf registration statement that is required to be effective pursuant to the registration rights agreement on such date shall be effective on such date with respect to the applicable holder. The redemption price shall be payable in cash or in shares of common stock. Additionally, upon the occurrence of a change of control, the holders of Preferred Stock shall be entitled to receive in full a liquidating purchase in cash and in the amount per share of the Preferred Stock equal to the sum of (i) the liquidation preference plus (ii) accrued dividends with respect to such shares of Preferred Stock.
In connection with this financing, the Company also paid the entities affiliated with Sylebra, (a) a facility fee in the amount of $2.5 million, (b) an origination fee in the amount of $0.6 million, (c) an administrative fee in the amount of $0.3 million and (d) fees and expenses of the investor and its counsel, of approximately $0.4 million. The issuance costs related to the Facility Agreement were expensed as incurred as it failed to meet the equity classification guidance under ASC 815-40, and were deemed to be a derivative asset. The fair value of the derivative asset was not material as of and for the period ended March 31, 2024.
In addition, upon receipt of stockholder approval in December 2023, the Company issued to Sylebra 3,000,000 Series A Warrants to purchase shares of Common Stock at an exercise price of $5.00.
As of March 31, 2024, the Company had 3,000,000 Series A Warrants outstanding. The Series A Warrants were issued as consideration for entering into the Facility Agreement as discussed above. Each Series A Warrant entitles the holder to purchase one share of the Company’s common stock at a price of $5.00 per share. Each Series A Warrant is currently exercisable and expires in December 2027. Holders shall not have the right to exercise the Series A Warrants to the extent that after giving effect to such exercise, such person would beneficially own in excess of 19.9% of the Company’s outstanding common stock immediately after giving effect to such exercise.
The exercise price and number of shares of common stock issuable upon exercise of the Series A Warrants may be adjusted in certain circumstances including in the event of a stock dividend or split, subsequent rights offerings, pro rata purchases, merger, reorganization, recapitalization, or spin-off. However, the Series A Warrants will not be adjusted for issuances of shares of common stock at a price below their respective exercise prices. The Series A Warrants do not entitle the holders to any voting rights, dividends or other rights as a stockholder of the Company prior to being exercised for common stock.
The Company analyzed the Series A Warrants and determined that they are freestanding and do not exhibit any of the characteristics within ASC 480, and as such do not meet the characteristics of a liability under ASC 480. However, Series A Warrants do not meet all requirements for equity classification under ASC 815, and therefore are classified as aliability on the Company’s consolidated balance sheets.
Note 10. Capital Structure
As of March 31, 2024, the Company was authorized to issue up to 422,000,000 shares of common stock, each with a par value of $0.0001 per share.
Preferred Stock
As of March 31, 2024, the Company was authorized to issue up to 10,000,000 shares of preferred stock, each with a par value of $0.0001 per share. As of March 31, 2024 and December 31, 2023, no shares of preferred stock were issued and outstanding.
Warrants
As of March 31, 2024, the Company had 2,414,975 public and 76,800 private warrants outstanding. Each warrant entitles the registered holder to purchase one share of common stock at a price of $57.50 per share. Additionally, the Company also issued 3,000,000 Series A Warrants issued in connection with the facility agreement. Each Series A Warrants entitles the registered holder to purchase one share of common stock at an exercise price of $5.00 per share.
Note 11. Earnings (Loss) Per Share
The following table sets forth the computation of the basic and diluted net loss per share attributable to common stockholders for the periods presented (in thousands, except per share data):
| Three Months Ended March 31, | ||
|---|---|---|
| 2024 | 2023 | |
| Numerator: | ||
| Net loss attributable to common stockholders | $(35,326) | $(35,174) |
| Denominator: | ||
| Weighted average shares of common stock outstanding — Basic and Diluted | 52,742,725 | 43,925,565 |
| Net loss per share attributable to common stockholders — Basic and Diluted | $(0.67) | $(0.80) |
The following table presents the potential common shares outstanding that were excluded from the computation of diluted net loss per share of common stock as of the periods presented because including them would have been anti-dilutive:
| Three Months Ended March 31, | ||
|---|---|---|
| 2024 | 2023 | |
| Common stock options issued and outstanding | 2,386,503 | 2,634,606 |
| Restricted stock units | 5,484,398 | 4,348,913 |
| Performance-based restricted stock units | 1,911,765 | — |
| Common stock warrants | 2,491,775 | 2,491,775 |
| Series A warrants | 3,000,000 | — |
| Total | 15,274,441 | 9,475,294 |
Note 12. Stock-based Compensation
Stock Options
The Company maintains the 2016 Stock Incentive Plan and the 2021 Incentive Award Plan (the “Stock Plans”) under which incentive stock options, non-qualified stock options and restricted stock units (“RSU”) may be granted to employees. Under the Stock Plans, the Company has 3,677,480 shares available for issuance as of March 31, 2024.
Under the terms of the Stock Plans, incentive stock options must have an exercise price at or above the fair market value of the stock on the date of the grant, while non-qualified stock options are permitted to be granted below fair market value of the stock on the date of grant. The majority of stock options granted have service-based vesting conditions only. The service-based vesting conditions vary, typically stock options vest over four years with 25% of stock options vesting on the first anniversary of the grant and the remaining 75% vesting monthly over the remaining 36 months. Option holders have a ten-year period to exercise the options before they expire.
A summary of the Company’s stock option activity, for three months ended March 31, 2024, was as follows:
| Number ofOptions | Weighted-AverageExercise Price | Weighted-AverageRemainingContractualLife (Years) | AggregateIntrinsic Value(in thousands) | |
|---|---|---|---|---|
| Outstanding as of December 31, 2023 | 2,414,730 | $2.79 | 5.73 | $4,004 |
| Granted | — | — | — | — |
| Exercised | (28,227) | 1.37 | — | — |
| Forfeited | — | — | — | — |
| Outstanding as of March 31, 2024 | 2,386,503 | $2.81 | 5.49 | $4,253 |
| Vested and exercisable as of March 31, 2024 | 2,317,344 | $2.46 | 5.42 | $4,251 |
| Vested and expected to vest as of March 31, 2024 | 2,386,503 | $2.81 | 5.49 | $4,253 |
There wereno options granted during the three months ended March 31, 2024. As of March 31, 2024, the Company had $0.5 million of unrecognized stock-based compensation expense related to the stock options. This cost is expected to be recognized over a weighted-average period of 1.65 years.
Restricted Stock Units (“RSUs”)and Performance-based Restricted Stock Units (“PBRSUs”)
In May 2023, the Company granted a total of 1,176,471 PBRSUs to certain executives that vest on achieving certain operational milestones as defined in the individual grant agreements subject to continued employment through 2025. Stock-based compensation expense is recognized over the expected performance achievement period of individual performance milestones when the achievement of each individual performance milestone becomes probable. If satisfaction of the performance condition is not probable, stock-based compensation cost recognition is deferred until it becomes probable. The Company reassesses the probability as to whether satisfaction of the performance condition is prob able on a quarterly basis, and stock-based compensation cost is adjusted based on the portion of the requisite service provided. These PBRSUs neither carry rights to dividends nor voting rights until the shares are issued or transferred to the recipient. Awards are forfeited if an employee leaves the Company before the PBRSUs vest or the performance period lapses. The weighted-average grant date PBRSU fair value of $5.10 per share is determined based upon the market closing price of the Company’s common stock on the date of grant. As of March 31, 2024, the total unrecognized compensation expense related to the performance-based PBRSUs was $1.3 million, which is expected to be amortized over a weighted-average period of 1.8 years.
In May 2023, the Company also granted a total of 735,294 market-based PBRSUs to certain executives that vest over a multi-year period, upon continued service and when the volume-weighted average price per share (“WVAP Average”) of the Company’s common stock for the preceding 30 consecutive trading days equals or exceeds the target stock price for the indicated year. The Company recognizes stock-based compensation based upon the grant date fair value on an accelerated attribution basis over the requisite service period of the award. Provided that the requisite service is rendered, the total fair value of the market-based PBRSUs at the date of grant is recognized as compensation expense even if the market condition is not achieved. However, the number of shares that ultimately vest can vary significantly with the achievement of the specified market criteria. These PBRSUs neither carry rights to dividends nor voting rights until the shares are issued or transferred to the recipient. Awards are forfeited if an employee leaves the Company before the PBRSUs vest. The weighted-average grant date fair value of the market-based PBRSUs was$1.40 per share. The Company estimated the fair value of the market-based PBRSUs award on the grant date using the Monte Carlo simulation model with the following assumptions:
| Expected term (years) | 0.5 - 4.7 | |
|---|---|---|
| Expected volatility | 70.9% | |
| Risk-free interest rate | 3.29% | |
| Dividend yield | 0% | |
| Share price | $5.10 |
As of March 31, 2024, the total unrecognized compensation expense related to the market-based PBRSUs was $0.7 million, which is expected to be amortized over a weighted-average period of 3 years.
The following table summarizes our RSU activity for the three months ended March 31, 2024:
| Shares | Weighted AverageGrant DateFair Valueper Share | |
|---|---|---|
| Outstanding as of December 31, 2023 | 5,204,177 | $9.65 |
| Granted | 889,257 | 5.05 |
| Released | (398,583) | 12.91 |
| Forfeited | (210,453) | 8.83 |
| Outstanding as of March 31, 2024 | 5,484,398 | $8.69 |
As of March 31, 2024, the Company had $39.6 million of unrecognized stock-based compensation expense related to the RSUs. This cost is expected to be recognized over a weighted-average period of 2.90 years. The above table excludes 1,911,765 PBRSUs granted to certain executive officers during the year ended December 31, 2023, and are outstanding as of March 31, 2024.
Compensation expense
Total stock-based compensation expense by function was as follows (in thousands):
| Three Months Ended March 31, | ||
|---|---|---|
| 2024 | 2023 | |
| Cost of revenue | $102 | $330 |
| Research and development expenses | 3,989 | 4,410 |
| General and administrative expenses | 907 | 1,119 |
| Sales and marketing expenses | 263 | 104 |
| Total | $5,261 | $5,963 |
Note 13. Income Taxes
There has historically beenno federal or state provision for income taxes because the Company has historically incurred operating losses and maintains a full valuation allowance against its net deferred tax assets. For the three months ended March 31, 2024 and 2023, the Company recognizedno provision for income taxes.
The federal and state net operating loss carryforwards may be subject to significant limitations under Section 382 and Section 383 of the Internal Revenue Code of 1986, as amended, and similar provisions under state law. The Tax Reform Act of 1986 contains provisions that limit the federal net operating loss carryforwards that may be used in any given year in the event of special occurrences, including significant ownership changes. The Company has completed an analysis as of December 31, 2022 and doesn’t expect any net operating loss carryforwards or tax credit carryforwards to expire due to a limitation.
Note 14. Commitments and Contingencies
Leases
The weighted-average remaining lease terms were 1.9 years and 2.0 yearsas of March 31, 2024 and December 31, 2023, respectively. The weighted-average discount rates were 6.32% and 6.04% as of March 31, 2024 and December 31, 2023, respectively. Operating lease cost for three months ended March 31, 2024 and 2023, was $1.0 million and $0.8 million, respectively.
The following is a maturity analysis of the annual undiscounted cash flows reconciled to the carrying value of the operating lease liabilities as of March 31, 2024 (in thousands):
| Operating Leases | |
|---|---|
| Remainder of 2024 | $2,974 |
| 2025 | 3,157 |
| 2026 | 729 |
| Total minimum lease payments | 6,860 |
| Less: imputed interest | (372) |
| Total lease liability | $6,488 |
Litigation
From time to time, the Company is involved in actions, claims, suits, and other proceedings in the ordinary course of business, including assertions by third parties relating to intellectual property infringement, breaches of contract or warranties, or employment-related matters. When it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated, the Company records a liability for such loss contingencies. The Company’s estimates regarding potential losses and materiality are based on the Company’s judgment and assessment of the claims utilizing currently available information. Although the Company will continue to reassess its reserves and estimates based on future developments, the Company’s objective assessment of the legal merits of such claims may not always be predictive of the outcome and actual results may vary from the Company’s current estimates.
Litigation – other matters
On March 7, 2024, a putative class action lawsuit was filed in the Court of Chancery of the State of Delaware against InterPrivate Acquisition Management LLC, InterPrivate LLC, and former directors and officers of InterPrivate Acquisition Corp (“IPV”). The lawsuit is captioned, Louis Smith v. Ahmed M. Fattouh, et al., (Del. Ch. 2024). Among other remedies, the complaint seeks damages and attorneys’ fees and costs. In connection with IPV’s March 12, 2021, merger transaction with Aeva Inc., Aeva granted certain indemnification rights to IPV’s former directors and officers. However, neither Aeva nor its current directors or officers are named as defendants in the complaint.
Indemnifications
In the ordinary course of business, the Company is not subject to potential obligations under guarantees that fall within the scope of FASB ASC Guarantees, (Topic 460), except for standard indemnification provisions that are contained within many of the Company’s customer agreements and give rise only to disclosure requirements prescribed by Topic 460. Indemnification provisions contained within the Company’s customer agreements are generally consistent with those prevalent in the Company’s industry. The Company has not incurred any obligations under customer indemnification provisions and does not expect to incur significant obligations in the future. Accordingly, the Company does not maintain accruals for potential customer indemnification obligations.
Note 15. Segment Information
The Company operates asone operating segment. Operating segments are defined as components of an enterprise for which separate financial information is evaluated regularly by the chief operating decision-maker (“CODM”), consisting of the Company’s chief executive officer and the Company’s chief technology officer as a group, in deciding how to allocate resources and assess the Company’s financial and operational performance. In addition, the Company’s CODM evaluates the Company’s financial information and resources and assesses the performance of these resources on a consolidated basis. As a result, the Company has determined that the Company’s business operates in a single operating segment. Since the Company operates as one operating segment, all required financial segment information can be found in the financial statements.
Long-Lived Assets
The following table sets forth the Company’s property, plant, and equipment, net by geographic region (in thousands):
| March 31, | December 31, | |
|---|---|---|
| 2024 | 2023 | |
| North America | $8,580 | $8,675 |
| Asia | 3,657 | 3,154 |
| Others | 315 | 285 |
| Total | $12,552 | $12,114 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.